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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To determine the effects on wound healing of a ’test and treat’ strategy for diagnosing and treating high levels of wound protease activity
in people with venous leg ulcers.
B A C K G R O U N D
Description of the condition
Venous leg ulcers are a common and recurring type of complex
wound (a wound which heals by secondary intention, i.e. by the
growth of new tissue rather than by primary closure). Problems
with the leg veins (such as damage to the valves, or blockages)
reduce the efficient return of blood to the heart and increase the
pressure in the leg veins (Ghauri 2010), whichmay result in venous
leg ulcers. The precise chain of events that links the high venous
pressures (chronic venous hypertension) with skin breakdown and
a chronic wound is not fully understood (Coleridge Smith 1988;
Valencia 2001).
Venous leg ulcers commonly occur on the gaiter region of the lower
leg (from just below the ankle up to mid calf ). A venous leg ulcer
is defined as any break in the skin that has either been present for
longer than six weeks or occurs in a person with a history of venous
leg ulceration. Differential diagnosis of the type of leg ulcer (i.e.
the underlying cause) is made by taking a clinical history, physi-
cal examination, laboratory tests and haemodynamic assessment
(RCN 2006; SIGN 2010). The latter typically includes an assess-
ment of arterial supply to the leg using the ankle brachial pressure
index (ABPI), measured using a hand-held Doppler ultrasound
scanner. Clinically significant arterial disease as a cause of ulcera-
tion is usually ruled out by an ABPI of at least 0.8 (Ashby 2014;
NICE 2012a; SIGN 2010). True venous ulcers are moist, shallow
and irregularly shaped and lie wholly or partly within the gaiter
area of the leg. Leg ulcers can be associated with venous disease in
combination with vascular disease, which impairs arterial blood
supply; in these instances they are said to have a ’mixed aetiology’.
Open skin ulceration due solely to limb ischaemia from vascular
disease is less common.
Venous disease is a chronic condition which is characterised by
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periods of ulceration (i.e., an openwound) followedby healing and
then recurrence. An early cross-sectional survey reported that half
of current or recent ulcers had been open for up to nine months
and that 35% of people with leg ulcers had experienced four or
more episodes (Callam 1987). This picture was supported by a
subsequent cross-sectional study (Nelzen 1994).
More recent analysis of almost 1200 patients documented a 24-
week healing rate of 76% and a recurrence at one year of 17%
(Gohel 2005). Cohort data from 20,000 people have shown that
initial wound area and duration accurately predict healing in ve-
nous leg ulcers (Margolis 2004). In this study, ulcers smaller than
10cm² with durations of less than 12 months at first visit had a
29% chance of not healing by the 24th week of care, whilst ulcers
larger than 10cm² with duration longer than 12 months had a
78% chance of not healing by 24 weeks (Margolis 2004). A small
cohort study has suggested that percentage change in area over
the first four weeks of treatment may be an indicator of whether
a wound will heal within 24 weeks (Kantor 2000). Older age has
been identified as an independent risk factor for delayed healing
(Gohel 2005) while slow healing is also a risk factor for recurrence,
possibly because it reflects the extent of underlying venous insuf-
ficiency (Gohel 2005).
Accurate, current estimates of leg ulcer prevalence are hard to iden-
tify because most surveys do not differentiate between causes of leg
ulceration, or do so per limb but not per patient (Moffatt 2004;
Srinivasaiah 2007; Vowden 2009a). Estimates of the prevalence
of open leg ulceration (any cause) range from 0.4 to 4.8 cases per
1000 (Graham 2003; Johnson 1995;Walker 2002), with the point
prevalence of venous leg ulceration in Australian and European
studies being between 0.1% and 0.3% (Nelzen 2008). A recent
estimate suggests that venous ulceration has a point prevalence of
0.29 cases per 1000 in the United Kingdom (UK), whilst mixed
arterial/venous leg ulceration has a point prevalence of 0.11 per
1000 (Hall 2014).
Venous ulcers are painful, can be malodorous and prone to in-
fection, and may severely affect patients’ mobility and quality
of life. The presence of leg ulceration has been associated with
pain, restriction of work and leisure activities, impaired mobility,
sleep disturbance, reduced psychological well-being and social iso-
lation (Herber 2007; Persoon 2004). In severe cases, ulceration
can lead to limb amputation although this may be more common
in patients with comorbid arterial insufficiency (Dumville 2009;
Nelzen 1997; Valencia 2001). Recent research suggests that peo-
ple with complex wounds, including those with venous leg ulcers,
commonly see complete wound healing as the most important
outcome to them (Madden 2014).
The financial cost of treating an unhealed leg ulcer in the UK has
been estimated at around GBP 1700 per year (price year 2012)
(Ashby 2014). Another evaluation estimated the average cost of
treating a venous leg ulcer in the UK (based on costs for material
for dressing changes) as between EUR 814 and EUR 1994 and,
in Sweden as lying between EUR 1332 and EUR 2585 (price year
2002), with higher costs associated with larger and more chronic
wounds (Ragnarson Tennvall 2005). Data from a German study,
which estimated total costs including those classified as indirect
or intangible costs, estimated mean annual costs of leg ulcers as
EUR 9060 per patient (price year 2006). This figure is higher than
other estimates because it includes non-health service costs to the
patient and to society (Augustin 2012). In Bradford, UK, GBP
1.69 million was spent on dressings and compression bandages,
and GBP 3.08 million on nursing time (estimates derived from
resource use data for all wound types) during the financial year
2006 to 2007 (Vowden 2009b).
The first line treatment for venous leg ulcers is compression ther-
apy in the form of bandages, stockings or mechanical devices
(O’Meara 2012).This application of external pressure around the
lower leg assists venous return and reduces venous reflux (Woo
2013). Alongside compression, wound dressings are commonly
applied to open ulcers. The primary rationale for using a dressing
is to protect the surface of the ulcer; however other considerations
such as absorption of exudate or antimicrobial properties also play
a role in treatment selection (O’Meara 2014).Other treatments for
venous leg ulcers include venous surgery (removal of incompetent
superficial veins) (Gohel 2007) and drugs such as pentoxifylline
(Jull 2012). Other standard therapeutic approaches for complex
wounds, such as optimising nutrition, and debridement (removal
of dead, damaged or infected tissue), may also be offered. Despite
these approaches, as discussed above, many venous leg ulcers re-
main hard to heal and further specialist treatments may be con-
sidered.
Description of the intervention
A ’test and treat strategy’ involves the use of a diagnostic/prognos-
tic test or assessment which precedes the potential use of a ther-
apeutic intervention (a treatment): the use and/or timing of the
treatment being dependent on the results of the test. A diagnostic
test determines the current state of disease while a prognostic test
indicates the likely future course of the disease process (Rector
2012).
Evaluations of test and treat strategies assess the use of combina-
tions of testing and treating, as opposed to evaluating diagnostic
test accuracy, or the effects of an treatment, separately. Test and
treat approaches are therefore the best method for implementing
a test where we need to consider both its diagnostic properties
(i.e. sensitivity and specificity) and the healthcare outcomes from
an effective test for the relevant indication (Ferrante di Ruffano
2012; Fryback 1991; Guyatt 1986; Lord 2006). As such, test and
treat evaluations are pragmatic and give an indication of the real
life results of implementing the strategy in terms of its impact on
patient outcomes (Bossuyt 2009).
Just as with therapeutic interventions alone, the gold standard for
assessing the impact of a test plus a treatment strategy is the ran-
domised controlled trial (RCT) (Lord 2009). Guidance on assess-
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ing the impact of tests in health care has been issued by various
agencies including the UKNational Institute for Health and Care
Excellence (NICE 2012b) and the United States (US) Agency for
Healthcare Research and Quality (AHRQ 2012; Rector 2012).
In this review we evaluate test and treat interventions for high
protease activity in venous leg ulcers. This involves the use of a test
for high protease levels in venous leg ulcers as well as subsequent
targeted treatment decisions (possible use of treatments designed
to reduce protease levels) which follow the test.
Protease activity in wounds
Proteases are enzymes which break down proteins into their con-
stituent peptides and amino acids. The action of different pro-
teases tends to be restricted to different proteins. The principal
proteases involved in wound healing are the matrix metallopro-
teinases (MMPs) and the serine proteases which breakdown ex-
tracellular matrix (ECM) and connective tissue proteins such as
collagen and elastin (Ladwig 2002; Nwomeh 1999).
Proteases are thought to play key roles in the normal wound heal-
ing process, being active in three of the phases of wound healing:
inflammation, proliferation and remodelling (Trengove 1999). In
the inflammation phase, proteases are used for the removal of
damaged ECM, bacteria and foreign material (aiding autolytic
debridement); in the proliferation phase proteases have a role in
the degradation of capillary basement membrane for angiogenesis
(growth of new capillary blood vessels) and in aiding detachment
and migration of cells; and in the remodelling phase protease ac-
tivity contributes to contraction and remodelling of scar ECM. It
is thought that there is a burst of protease activity at the start of
acute wound healing and, in normally-healing wounds, an activity
peak in the first two to three days followed by a decline to very low
levels after one week (Nwomeh 1998). Proteases may be present in
an active or inactive state and protease activity is regulated through
complex feedback mechanisms within the wound environment;
only activated proteases have an impact on the wound healing
process (McCarty 2013; Nwomeh 1999; Yager 2002).
In non-healing wounds it is thought that a complex inflammatory
mechanism may result in proteases reaching higher levels and also
persisting for longer than in healing wounds (Trengove 1999).
Correlations between elevated levels ofMMPs and delayed healing
have been documented in pressure ulcers (Ladwig 2002) and foot
ulcers in people with diabetes (Liu 2009) as well as in venous
leg ulcers (Mwaura 2006; Serra 2013). However, there is limited
evidence for a causal relationship between protease activity and
wound healing.
Protease-modulating treatments
Novel treatments have beendesigned tomodify the chronicwound
environment by substantially reducing the activity of key pro-
teases. The principle of such protease-modulating matrix treat-
ments is both to absorb and bind excess proteases fromwound flu-
ids, thereby reducing levels of protease at the wound bed (Cullen
2002). The treatments do not, however, affect the expression of
proteases on a cellular level (Lobmann 2006).
Interventions that reduce harmful levels of protease activity may
potentially promote healing in wounds with persistently high pro-
tease activity. However evidence for this from RCTs has been lim-
ited across unselected wounds of different aetiologies, including
venous leg ulcers (e.g. Andriessen 2009;Chin2003;Kakagia 2007;
Nisi 2005; Veves 2002). There is extremely limited evidence from
a very small industry-sponsored study that screened wounds may
respond better to protease-modulating treatment relative to all
wounds (Cullen 2011).
Treatments can target specific proteases or can be broader spec-
trum, designed to inhibit all protease activity. Common protease-
modulating treatments and their properties are described below.
Products are listed by their generic names and, when possible, with
examples of corresponding trade names and manufacturers. Both
dressings and ointments are available; some dressings have silver
ions incorporated,which are intended to reducewoundpathogens.
Types of protease-modulating treatment which are listed in the
British National Formulary (BNF 2014) include the following:
• Starch-based ointment: Cadesorb® (Smith & Nephew)
• Collagen matrix (bovine cartilage): Catrix® (Cranage)
• Gel, alginate and propylene glycol with extracellular matrix
proteins: Xelma® (Mölnlycke)
• Collagen and oxidised regenerated cellulose matrix dressing:
Promogran® (Systagenix)
• Collagen, silver and oxidised regenerated cellulose matrix
dressing: Promogran® Prisma® (Systagenix)
• Cellulose acetate matrix, impregnated with polyhydrated
ionogens ointment in polyethylene glycol basis dressing:
Tegaderm® Matrix (3M)
• Adherent polymer matrix dressing containing nano-
oligosaccharide factor (NOSF), with polyurethane foam film
backing: UrgoStart® (Urgo)
• Non-adherent wound contact dressing containing NOSF:
UrgoStart® Contact (Urgo).
This list is not exhaustive and other wound dressings such as Aqua-
cel® (ConvaTec) are sometimes listed as having protease-mod-
ulating effects (Wound Care Handbook). A pragmatic approach
will be adopted, and, where such dressings are used in a protease-
modulating capacity we will include them in the review.
How the intervention might work
Very weak evidence suggests an inverse association between pro-
tease levels and healing in an unadjusted analysis of a mixed sam-
ple which included venous leg ulcers, foot ulcers in people with
diabetes, and pressure ulcers (Cullen 2011; Serena 2011). On this
basis, a test and treat process has been proposed, which involves
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the testing of venous leg ulcers for levels of protease activity fol-
lowed by targeted treatment of those deemed to have high levels of
protease activity (and alternative care for the remaining wounds)
(Systagenix 2013). This might mean that only wounds where high
protease activity is present receive treatment designed to lower it.
It is suggested that this strategy may reduce the time taken to heal
for the wounds receiving targeted treatment, whilst avoiding un-
necessary, expensive and potentially harmful use of the protease-
modulating treatments in wounds where protease activity levels
were not increased.
Why it is important to do this review
Venous leg ulcers are a relatively common type of complex wound
that have a negative impact on people’s lives and incur high costs
for health services and society. Leg ulcers are painful, sometimes
malodorous, prone to infection, and may severely affect patients’
mobility and quality of life, and in severe cases, there is a risk of
limb amputation. There are a number of treatments for venous
leg ulcers, but many ulcers prove hard to heal.
There is awidespread view among experts in the field that proteases
have an important role in wound healing and that a point of
care test for elevated activity of commonly identified proteases has
value (International Consensus 2011; Barrett 2011; Snyder 2011;
Snyder 2012). Identification of wounds in which there is elevated
protease activity is not considered possible on the basis of clinical
examination alone; delayed wound healing is not proposed to be
a universal indicator (Sibbald 2012; Snyder 2012). Limited data
from an industry-sponsored study found that only 28% of 162
non-healing wounds of mixed aetiology were determined to have
high protease activity (Serena 2011).
However, although a test for protease activity is now available, the
impact of its use, in combination with subsequent targeted treat-
ments with protease-modulating therapies where indicated, is un-
clear, and we are not aware of other reviews that address this ques-
tion. A Cochrane review of the use of protease-modulating dress-
ings in venous leg ulcers is currently underway (Westby 2014). A
review of the diagnostic test accuracy of protease activity tests is
also planned (Dumville 2015 [personal communication]).
In the current review we will assess the impact of testing venous
leg ulcers for high levels of protease activity and treating those
which record a positive test result; we will therefore be assessing
the relative effectiveness of one or more tests for protease activ-
ity (together with thresholds for treatment) and the subsequent
protease-modulating treatments. Our review will also compare a
strategy of test and treat with non-directed usual care.
O B J E C T I V E S
To determine the effects on wound healing of a ’test and treat’
strategy for diagnosing and treating high levels of wound protease
activity in people with venous leg ulcers.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include published andunpublished randomised controlled
trials (RCTs), including cluster RCTs, irrespective of the language
of report. We will exclude quasi-randomised studies. We will only
include RCTs reported only as abstracts when available data (either
from the abstract itself or from the study authors) are sufficient
for reasonable data extraction.
Types of participants
We will include trials recruiting adults described as having venous
leg ulcers, managed in any setting. We will accept study authors’
definitions of venous leg ulcers and will note the diagnostic meth-
ods and criteria used.
We will include trials which recruited people with venous leg ul-
cers and those with other types of complex wounds if the results
for people with venous leg ulcers are presented separately or are
available from the authors.
We will include participants at any stage in their treatment path-
way, e.g. participants with or without hard to heal ulcers and with
or without clinical infection of ulcers.
Types of interventions
We will include any RCT which evaluates a test and treat strategy
for elevated protease activity in venous leg ulcers. In these studies
the use of a specific test and treat strategy will be the only system-
atic difference between treatment groups. This will include trials
in which all participants in the comparison arm received the same
protease-modulating treatment but where a test and treat strategy
was applied in the intervention arm as well as trials comparing test
and treatment combinations versus each other, versus other inter-
ventions, or versus standard care. This may include comparisons
of different test thresholds for the same test.
We will include RCTs whether or not compression therapy is
reported as a concurrent treatment as long as the study groups
received the same compression protocols. Where possible we
will assess the impact of concurrent compression therapy on
the treatment effect (see Subgroup analysis and investigation of
heterogeneity).
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We will exclude studies in which the test result is part of the inclu-
sion criteria, i.e. participants with a positive test result were ran-
domised to different protease-modulating treatments or to pro-
tease-modulating versus alternative treatments, as these will be
included in a concurrent review evaluating protease-modulating
matrix treatments for venous leg ulcers (Westby 2014).
Types of outcome measures
We list primary and secondary outcome measures below. If a trial
is otherwise eligible (correct study design, population and inter-
vention/comparator) but does not report a listed outcome, then
we will contact the study authors where possible in order to estab-
lish whether a relevant outcome was measured but not reported.
Trials will be included only where we are able to obtain data on a
listed outcome.
We will report outcome measures at the latest time point available
for a study (assumed to be length of follow-up if not specified)
and the time point specified in the methods as being of primary
interest (if this is different from the latest time point available).
Where appropriate, for all outcomes we will class (and categorise)
outcomes from:
• < 1 week to 8 weeks as short term;
• > 8 weeks to 24 weeks as medium term; and
• > 24 weeks as long term.
We will use our judgement to decide whether statistical pooling
within these time categories is appropriate.
Primary outcomes
The primary effectiveness outcome for this review is wound heal-
ing. Trialists use a range of different methods of measuring and
reporting this outcome. We will regard the following as the most
relevant and rigorous measures of wound healing:
• Time to complete wound healing (correctly analysed using
survival, time-to-event approaches). Ideally the outcome will be
adjusted for appropriate covariates, e.g. baseline ulcer area/
duration.
• Proportion of wounds completely healed during follow-up
(frequency of complete healing).
We will use authors’ definitions of complete wound healing; these
will be reported.
Where both of the outcomes above are reported, we will present
all data in a summary outcome table for reference but will focus on
reporting time to healing. When time is analysed as a continuous
measure, but it is not clear whether all wounds healed, we will
document the use of the outcome in the study, but we will not
extract, summarise or use the data in any meta-analysis.
The primary safety outcome is all reported adverse events. Where
reported, we will extract data on all serious adverse events and
all non-serious adverse events where a clear methodology for the
collection of adverse event data was provided. This methodology
should make it clear whether events were reported at the partic-
ipant level or, where multiple events/person were reported, that
an appropriate adjustment has been made for data clustering. We
will not extract individual types of adverse events other than pain
or infection (see Secondary outcomes). We will note where events
are reported as being treatment-related.
Secondary outcomes
We will include the following secondary outcomes:
• Health-related quality of life: we will include quality of life
where it is reported using a validated scale such as the SF-36 or
EQ-5D or a validated disease-specific questionnaire such as the
Cardiff Wound Impact Schedule. Ideally reported data will be
adjusted for the baseline score. We will not include ad hoc
measures of quality of life that are unlikely to be validated and
would not be common to multiple trials.
• Pain scores: we will include pain (including pain at dressing
change) only where mean scores with a standard deviation are
reported using a scale validated for the assessment of pain levels,
such as a visual analogue scale (VAS).
• Change (and rate of change) in wound size, with
adjustment for baseline size (we will contact study authors to
request adjusted means when not presented). When change or
rate of change in wound size is reported without adjustment for
baseline size, use of the outcome in the study will be
documented, but data will not be extracted, summarised or used
in any meta-analysis.
• Change in wound infection status (as defined by the study
authors): we will include measures of incident cases of infection
and cases of existing infections being resolved. We will not extract
data on microbiological assays not clearly linked to a diagnosis of
infection. We will use authors’ definitions of infection.
• Resource use (when presented as a mean with standard
deviation) including measures of resource use such as
appointments for undergoing tests and receiving test results,
number of dressing changes, number of nurse visits, length of
hospital stay, need for other interventions.
• Costs associated with resource use (including estimates of
cost-effectiveness).
Search methods for identification of studies
Electronic searches
We will search the following electronic databases:
• The Cochrane Wounds Group Specialised Register.
• The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library) (latest issue).
• Ovid MEDLINE (1946 to present).
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• Ovid EMBASE (1974 to present).
• EBSCO Cumulative Index to Nursing and Allied Health
Literature (CINAHL) (1982 to present).
We will use the following provisional search strategy in CEN-
TRAL:
#1 MeSH descriptor: [Leg Ulcer] explode all trees
#2 (varicose ulcer* or venous ulcer* or leg ulcer* or stasis ulcer*
or crural ulcer* or ulcus cruris or ulcer cruris):ti,ab,kw (Word
variations have been searched)
#3 {or #1-#2}
#4 MeSH descriptor: [Peptide Hydrolases] explode all trees
#5 (protease* or proteinase* or metalloproteinase* or peptidase*
or “peptide hydrolase” or “peptide hydrolases” or “proteolytic en-
zymes” or “proteolytic enzyme” or esteroprotease*):ti,ab,kw (Word
variations have been searched)
#6 {or #4-#5}
#7 {and #3, #6} in Trials
We will adapt this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We will combine the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision) (Lefebvre 2011).We
will combine the EMBASE search with the Ovid EMBASE filter
developed by the UK Cochrane Centre (Lefebvre 2011). We will
combine the CINAHL searches with the trial filters developed
by the Scottish Intercollegiate Guidelines Network (SIGN 2011).
There will be no restrictions with respect to language, date of pub-
lication or study setting.
We will also search the following clinical trials registries:
• ClinicalTrials.gov (http://www.clinicaltrials.gov/).
• WHO International Clinical Trials Registry Platform (http:
//apps.who.int/trialsearch/Default.aspx).
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/).
A shared search strategy will be employed for the current review
and the review of effectiveness of protease-modulating treatments
(Westby 2014).
Searching other resources
We will try to identify other potentially-eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, as well as relevant systematic reviews, meta-analyses and
health technology assessment reports.We will contact correspond-
ing authors of trials and themanufacturers and distributors of pro-
tease-modulating treatments or of tests for wound protease activ-
ity including Systagenix. We will search the websites and briefing
documentation of regulatory bodies including the US Food and
Drug Administration and the European Medical Association.
Data collection and analysis
Selection of studies
Two review authors will independently assess the titles and ab-
stracts of the citations retrieved by the searches for relevance. After
this initial assessment, we will obtain full text copies of all stud-
ies considered to be potentially relevant. Two review authors will
independently check the full papers for eligibility; disagreements
will be resolved by discussion and, where required, the input of a
third review author. Where the eligibility of a study is unclear we
will attempt to contact study authors. We will record all reasons
for exclusion of studies for which we had obtained full copies.
We will complete a PRISMA flowchart to summarise this process
(Liberati 2009).
Where studies have been reported in multiple publications/re-
ports, we will obtain all associated publications. Whilst the study
will be included only once in the review, we will extract data from
all reports to ensure that all available relevant data are obtained.
Data extraction and management
Wewill extract and summarise details of the eligible studies.Where
possible we will extract data by treatment group for the prespec-
ified interventions and outcomes in this review. Data will be ex-
tracted independently by two review authors; discrepancies will be
resolved through discussion or by consultation with a third author.
Where data are missing from reports, we will attempt to contact
the study authors to request this information.
Where a study with more than two intervention arms is included,
only data from intervention and control groups that meet the
eligibility criteria will be extracted. Where the reported baseline
data relate to all patients rather than to those in relevant treatment
arms, the data for the whole trial will be extracted and this will be
noted.
Outcome data will be collected for relevant time points as de-
scribed in the Types of outcome measures section, and will be ex-
tracted on an intention-to-’test and treat’ basis. However, where
possible, we will also extract separate outcome data for those in
the intervention arm who have positive results followed by pro-
tease-modulating treatment and those who have negative results
followed by a different treatment.
Where possible we will extract the following data:
• bibliographic data including date of completion/publication
• country of origin
• unit of randomisation (participant/ulcer)
• unit of analysis
• trial design, e.g. parallel; cluster
• care setting
• number of participants randomised to each trial arm and
number included in final analysis
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• eligibility criteria and key baseline participant data
including duration of venous insufficiency and current ulcer(s)
• details of treatment regimen received by each group
including the nature, threshold and timing of test and the
nature, timing and duration of subsequent treatment initiation.
Details of treatment for participants with negative test results
will also be reported
• details of any co-interventions
• number (%) of patients with positive and negative test
results and the number of patients receiving each treatment
• primary and secondary outcome(s) (with definitions and,
where applicable, time points)
• outcome data for primary and secondary outcomes (by
group) including outcomes for participants randomised to the
intervention(s) but with negative test results
• duration of follow-up
• number of withdrawals (by group), and number of
withdrawals (by group) due to adverse events. Where possible
separate data will be extracted for participants in the intervention
group(s) with positive and negative test results
• publication status of trial
• source of funding for trial.
Assessment of risk of bias in included studies
Two review authors will independently assess included studies
using the Cochrane Collaboration tool for assessing risk of bias
(Higgins 2011a). This tool addresses six specific domains: se-
quence generation, allocation concealment, blinding, incomplete
data, selective outcome reporting and other issues (Appendix 1).
In this review we will record issues with unit of analysis, for ex-
ample where a cluster trial has been undertaken but analysed at
the individual level in the study report. For this review we will not
assess blinding of patients and personnel as this is unlikely to be
possible in a trial of the interventions included (testing and treat-
ing according to test results); all other domains will be assessed.We
will assess blinding of outcome assessment and completeness of
outcome data for each of the review outcomes separately. Because
this is a review of a test and treat process, we will also consider dif-
ferences in completeness of outcome data between patients with
positive versus negative test results in the intervention group(s).
We will present our assessment of risk of bias using two ’Risk of
bias’ summary figures; one which is a summary of bias for each
item across all studies, and a second which shows a cross-tabula-
tion of each trial by all of the ’Risk of bias’ items. We will sum-
marise a study’s risk of selection bias, detection bias, attrition bias,
reporting bias and other bias. We anticipate that in many com-
parisons blinding of participants and personnel may not be possi-
ble.Therefore the assessment of the risk of detection bias will focus
on whether blinded outcome assessment was reported. (Because
wound healing can be a subjective outcome, it can be at high risk
of measurement bias when outcome assessment is not blinded).
For trials using cluster randomisation, we will also examine the
risk of bias considering: recruitment bias, baseline imbalance, loss
of clusters, incorrect analysis and comparability with individually
randomised trials (Higgins 2011b) (Appendix 2).
Measures of treatment effect
Time-to-event data (e.g. time to complete wound healing) will be
reported as hazard ratios (HRs) when possible, in accordance with
the methods described in the Cochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011). If studies reporting time-to-
event data (e.g. time to healing) do not report an HR, then, when
feasible, we plan to estimate this using other reported outcomes,
such as numbers of events, through the application of available
statistical methods (Parmar 1998; Tierney 2007). For dichoto-
mous outcomes, we will calculate the risk ratio (RR) with 95%
confidence intervals (CIs). For continuous outcome data, we will
use the mean difference (MD) with 95% CIs for trials that use the
same assessment scale. When trials use different assessment scales,
we will use the standardised mean difference (SMD) with 95%
CIs.
Unit of analysis issues
Where studies have been randomised at the participant level and
outcomes measured at the wound level, for example for wound
healing, we will treat the participant as the unit of analysis when
the number of wounds assessed appears to be equal to the number
of participants (e.g. one wound per person).
A possible unit of analysis issue that may occur is that randomi-
sation has been carried at the participant level with the allocated
treatment used on multiple wounds per participant (or perhaps
only on some participants) but data are presented and analysed
per wound (clustered data).
In cases where included studies contain some or all clustered data
we plan to report this, noting whether data had been (incorrectly)
treated as independent. We will record this as part of the risk of
bias assessment. We do not plan to undertake further calculation
to adjust for clustering as part of this review.
Dealing with missing data
It is common to have data missing from trial reports. Excluding
participants from the analysis post randomisation or ignoring par-
ticipants who are lost to follow-up compromises the randomisa-
tion and may introduce bias into the trial. If it is thought that
study authors might be able to provide some missing data, we will
contact them; however, it is likely that data will often be missing
because of loss to follow-up. In individual studies, when data on
the proportion of ulcers healed are presented, we plan to assume
that randomly assigned participants not included in an analysis
had an unhealed wound at the end of the follow-up period (i.e.
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they will be considered in the denominator but not in the numer-
ator).
When a trial does not specify participant group numbers before
dropout, we will present only complete case data. For time-to-
healing analysis using survival analysis methods, dropouts should
be accounted for as censored data. Hence all participants will be
contributing to the analysis.We acknowledge that such analysis as-
sumes that dropouts are missing at random and there is no pattern
of missingness. We will present data for all secondary outcomes as
a complete case analysis.
For continuous variables, e.g. length of hospital stay, and for all
secondary outcomes we will present available data from the study
reports/study authors and do not plan to impute missing data.
Where measures of variance are missing we will calculate these
wherever possible (Higgins 2011a). If calculation is not possible
we will contact study authors. Where these measures of variation
remain unavailable and cannot be calculated, we will exclude the
study from any relevant meta-analyses that we conduct.
Assessment of heterogeneity
Assessment of heterogeneity can be a complex, multi-faceted pro-
cess. Firstly, we will consider clinical and methodological het-
erogeneity: that is the degree to which the included studies vary
in terms of participant, intervention, outcome and characteris-
tics such as length of follow-up. This assessment of clinical and
methodological heterogeneity will be supplemented by informa-
tion regarding statistical heterogeneity - assessed using the Chi²
test (a significance level of P < 0.10 will be considered to indi-
cate statistically significant heterogeneity) in conjunction with I²
measure (Higgins 2003). I² examines the percentage of total vari-
ation across RCTs that is due to heterogeneity rather than chance
(Higgins 2003). Very broadly, we will consider that I² values of
25%, or less, may mean a low level of heterogeneity (Higgins
2003), and values of more than 75%, or more, indicate very high
heterogeneity (Deeks 2011). We will also examine the variability
of the point estimates and the overlap of the confidence intervals,
when I² values are less than 50%. Where there is evidence of high
heterogeneity we will attempt to explore this further; see Data
synthesis.
Assessment of reporting biases
Reporting biases arise when the dissemination of research findings
is influencedby the nature anddirectionof results. Publication bias
is one of a number of possible causes of ’small study effects’, that
is, a tendency for estimates of the intervention effect to be more
beneficial in smaller RCTs. Funnel plots allow a visual assessment
of whether small study effects may be present in a meta-analysis.
A funnel plot is a simple scatter plot of the intervention effect es-
timates from individual RCTs against some measure of each trial’s
size or precision (Sterne 2011). Funnel plots are only informative
when there are a substantial number of studies included in an
analysis; we plan to present funnel plots for meta-analyses which
include at least 10 RCTs using RevMan 5.3 (RevMan 2014).
Data synthesis
We will combine details of included studies in narrative review ac-
cording to the comparison between intervention and comparator,
the population and the time point of the outcome measurement.
We will also use the timing of the protease activity test and the
threshold for a positive result to structure the synthesis. We will
consider clinical and methodological heterogeneity and undertake
pooling when studies appear appropriately similar in terms of ul-
cer characteristics, intervention type, duration of treatment and
outcome assessment.
In terms of meta-analytical approach, in the presence of clinical
heterogeneity (review author judgement) and/or evidence of sta-
tistical heterogeneity we will use the random-effects model. We
will only use a fixed-effect approach when clinical heterogeneity
is thought to be minimal and statistical heterogeneity is estimated
as non-statistically significant for the Chi² value and 0% for the
I² assessment (Kontopantelis 2012). We will adopt this approach
as it is recognised that statistical assessments can miss potentially
important between-study heterogeneity in small samples, hence
the preference for the more conservative random-effects model
(Kontopantelis 2013). Where clinical heterogeneity is thought to
be acceptable or of interest we may meta-analyse even when sta-
tistical heterogeneity is high but we will attempt to interpret the
causes behind this heterogeneity and will consider using meta-re-
gression for that purpose, if possible (Thompson 1999; Thompson
2002).
Wewill present data using forest plots where possible. For dichoto-
mous outcomes we will present the summary estimate as an RR
with 95% CI. Where continuous outcomes are measured in the
sameway across studies, we plan topresent a pooledMDwith 95%
CI; we plan to pool SMD estimates where studies measure the
same outcome using different methods. For time-to-event data,
we plan to plot (and, if appropriate, pool) estimates of HRs and
95%CIs as presented in the study reports using the generic inverse
variance method in RevMan 5.3 (RevMan 2014). Where time to
healing is analysed as a continuous measure but it is not clear if all
wounds healed, we will document the use of the outcome in the
study but will not summarise or use the data in any meta-analysis.
’Summary of findings’ tables
We will present the main results of the review in ’Summary of
findings’ tables. These tables present key information concerning
the quality of the evidence, the magnitude of the effects of the
interventions examined and the sum of available data for the main
outcomes (Schünemann 2011a). The ’Summary of findings’ ta-
bles also include an overall grading of the evidence related to each
of the main outcomes using the GRADE (Grades of Recommen-
dation, Assessment, Development and Evaluation) approach. The
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GRADE approach defines the quality of a body of evidence as the
extent to which one can be confident that an estimate of effect or
association is close to the true quantity of specific interest. The
quality of a body of evidence involves consideration of within-
trial risk of bias (methodological quality), directness of evidence,
heterogeneity, precision of effect estimates and risk of publication
bias (Schünemann 2011b). We plan to present the following out-
comes in the ’Summary of findings’ tables for each comparison:
• Time to complete ulcer healing when analysed using
appropriate survival analysis methods.
• Proportion of ulcers completely healed during the trial
period.
• Study-defined serious and non-serious adverse events.
Subgroup analysis and investigation of heterogeneity
When possible we will perform subgroup analyses according to
whether the intervention was delivered in conjunction with com-
pression therapy or not. RCTs in which it is unclear whether con-
current compression therapy was used will be excluded from these
analyses.
When possible we will conduct subgroup analyses based on the
type of test for protease activity employed and/or the threshold
used to define a positive test result. For example laboratory-based
assays could be compared to point-of-care tests.
When possible, we will explore the influence of risk of bias on
effect size. We will assess the influence of removing from meta-
analyses studies classed as having high and unclear risk of bias. We
will explore subgroups of studies that are assessed as having low
risk of bias in all key domains, namely selection bias, detection
bias and attrition bias.
Elements of this methods section are based on the standard
Cochrane Wounds Group Protocol Template.
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A P P E N D I C E S
Appendix 1. Assessment of risk of bias
1. Was the allocation sequence randomly generated?
Low risk of bias
The investigators describe a random component in the sequence generation process such as: referring to a random number table; using
a computer random-number generator; coin tossing; shuffling cards or envelopes; throwing dice; drawing of lots.
High risk of bias
The investigators describe a non-random component in the sequence generation process. Usually, the description would involve some
systematic, non-random approach, for example: sequence generated by odd or even date of birth; sequence generated by some rule
based on date (or day) of admission; sequence generated by some rule based on hospital or clinic record number.
Unclear
Insufficient information about the sequence generation process provided to permit a judgement of low or high risk of bias.
2. Was the treatment allocation adequately concealed?
Low risk of bias
Participants and investigators enrolling participants could not foresee assignment because one of the following, or an equivalent
method, was used to conceal allocation: central allocation (including telephone, web-based and pharmacy-controlled randomisation);
sequentially-numbered drug containers of identical appearance; sequentially-numbered, opaque, sealed envelopes.
High risk of bias
Participants or investigators enrolling participants could possibly foresee assignments and thus introduce selection bias, such as allocation
based on: using an open random allocation schedule (e.g. a list of randomnumbers); assignment envelopes were usedwithout appropriate
safeguards (e.g. if envelopes were unsealed or non-opaque or not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure.
Unclear
Insufficient information provided to permit a judgement of low or high risk of bias. This is usually the case if themethod of concealment
is not described or not described in sufficient detail to allow a definite judgement, for example if the use of assignment envelopes is
described, but it remains unclear whether envelopes were sequentially numbered, opaque and sealed.
3. Blinding - was knowledge of the allocated interventions adequately prevented during the study?
Low risk of bias
Any one of the following.
• No blinding, but the review authors judge that the outcome and the outcome measurement are not likely to be influenced by
lack of blinding.
• Blinding of participants and key study personnel ensured, and unlikely that the blinding could have been broken.
• Either participants or some key study personnel were not blinded, but outcome assessment was blinded and the non-blinding of
others was unlikely to introduce bias.
High risk of bias
Any one of the following.
• No blinding or incomplete blinding, and the outcome or outcome measurement is likely to be influenced by lack of blinding.
• Blinding of key study participants and personnel attempted, but likely that the blinding could have been broken and the
outcome or outcome measurement is likely to be influenced by lack of blinding.
• Either participants or some key study personnel were not blinded, and the non-blinding was likely to introduce bias.
Unclear
Either of the following.
• Insufficient information provided to permit a judgement of low or high risk of bias.
• The study did not address this outcome.
4. Were incomplete outcome data adequately addressed?
Low risk of bias
Any one of the following.
• No missing outcome data.
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• Reasons for missing outcome data unlikely to be related to true outcome (for survival data, censoring unlikely to be introducing
bias).
• Missing outcome data balanced in numbers across intervention groups, with similar reasons for missing data across groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was not enough to have
a clinically relevant impact on the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes was not enough to have a clinically relevant impact on observed effect size.
• Missing data have been imputed using appropriate methods.
High risk of bias
Any one of the following.
• Reason for missing outcome data likely to be related to true outcome, with either imbalance in numbers or reasons for missing
data across intervention groups.
• For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk was enough to induce
clinically relevant bias in the intervention effect estimate.
• For continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing
outcomes was enough to induce clinically relevant bias in observed effect size.
• ‘As-treated’ analysis done with substantial departure of the intervention received from that assigned at randomisation.
• Potentially inappropriate application of simple imputation.
Unclear
Either of the following.
• Insufficient reporting of attrition/exclusions to permit a judgement of low or high risk of bias (e.g. number randomised not
stated, no reasons for missing data provided).
• The study did not address this outcome.
5. Are reports of the study free of suggestion of selective outcome reporting?
Low risk of bias
Either of the following.
• The study protocol is available and all of the study’s pre-specified (primary and secondary) outcomes that are of interest in the
review have been reported in the pre-specified way.
• The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that
were pre-specified (convincing text of this nature may be uncommon).
High risk of bias
Any one of the following.
• Not all of the study’s pre-specified primary outcomes have been reported.
• One or more primary outcomes are reported using measurements, analysis methods or subsets of the data (e.g. subscales) that
were not pre-specified.
• One or more reported primary outcomes of the study were not pre-specified (unless clear justification for their reporting is
provided, such as an unexpected adverse effect).
• One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis.
• The study report fails to include results for a key outcome that would be expected to have been reported for such a study.
Unclear
Insufficient information provided to permit judgement of low or high risk of bias. It is likely that the majority of studies will fall into
this category.
6. Other sources of potential bias
Low risk of bias
The study appears to be free of other sources of bias.
High risk of bias
There is at least one important additional risk of bias. For example, the study:
• had a potential source of bias related to the specific study design used; or
• has been claimed to have been fraudulent; or
• had some other problem.
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Unclear
There may be a risk of bias, but there is either:
• insufficient information to assess whether an important risk of bias exists; or
• insufficient rationale or evidence that an identified problem will introduce bias.
Appendix 2. Risk of bias in cluster randomised trials
In cluster randomised trials, particular biases to consider include: (i) recruitment bias; (ii) baseline imbalance; (iii) loss of clusters; (iv)
incorrect analysis; and (v) comparability with individually randomised trials.
(i) Recruitment bias can occur when individuals are recruited to the trial after the clusters have been randomised, as the knowledge of
whether each cluster is an ‘intervention’ or ‘control’ cluster could affect the types of participants recruited.
(ii) Cluster randomised trials often randomise all clusters at once, so lack of concealment of an allocation sequence should not usually
be an issue. However, because small numbers of clusters are randomised, there is a possibility of chance baseline imbalance between the
randomised groups, in terms of either the clusters or the individuals. Although not a form of bias as such, the risk of baseline differences
can be reduced by using stratified or pair-matched randomisation of clusters. Reporting of the baseline comparability of clusters, or
statistical adjustment for baseline characteristics, can help to reduce concern about the effects of baseline imbalance.
(iii) Occasionally complete clusters are lost from a trial, and have to be omitted from the analysis. Just as for missing outcome data in
individually randomised trials, this may lead to bias. In addition, missing outcomes for individuals within clusters may also lead to a
risk of bias in cluster randomised trials.
(iv) Many cluster randomised trials are analysed by incorrect statistical methods, not taking the clustering into account. Such analyses
create a ‘unit of analysis error’ and produce over-precise results (the standard error of the estimated intervention effect is too small) and
P values that are too small. They do not lead to biased estimates of effect. However, if they remain uncorrected, they will receive too
much weight in a meta-analysis.
(v) In a meta-analysis including both cluster and individually randomised trials, or including cluster randomised trials with different
types of clusters, possible differences between the intervention effects being estimated need to be considered. For example, in a vaccine
trial of infectious diseases, a vaccine applied to all individuals in a community would be expected to be more effective than if the vaccine
was applied to only half of the people. Another example is provided by a discussion of a Cochrane review of hip protectors (Hahn 2005).
The cluster trials showed large positive effect whereas individually randomised trials did not show any clear benefit. One possibility is
that there was a ‘herd effect’ in the cluster randomised trials (which were often performed in nursing homes, where compliance with
using the protectors may have been enhanced). In general, such ‘contamination’ would lead to underestimates of effect. Thus, if an
intervention effect is still demonstrated despite contamination in those trials that were not cluster randomised, a confident conclusion
about the presence of an effect can be drawn. However, the size of the effect is likely to be underestimated. Contamination and ‘herd
effects’ may be different for different types of cluster.
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